Medicine, University of Colorado School of Medicine
Tasia Poinsatte, Colorado Director, Healing Advocacy Fund
Henny Lasley, Executive Director, One Chance to Grow Up
Richard Zane, MD, Executive Director of Emergency Services, UCHealth
Professor and Chair, Department of Emergency Medicine, University of
Colorado School of Medicine, introduced the presentation regarding
Colorado voters passing the measure to decriminalize psychedelic
mushrooms and create healing centers for psilocybin therapy.
Christopher Hoyt, MD, Medical Director, Rocky Mountain Poison and Drug
Center Professor and associate vice-chair, Department of Emergency
Medicine, University of Colorado School of Medicine, presented an
overview of psilocybin exposures, poison hotline, hallucinogenic
mushrooms, annual exposures to psychedelic substances reported to
United States (U.S.) poison centers, clinical effects, and medical outcome.
Councilmember Leinweber asked what the concerns regarding healing
centers are. Dr. Zane stated psilocybin is already in the community outside
of healing centers and are unregulated, but they believe this substance has
the potential to help people, but it is not approved by the U.S. Food and
Drug Administration (FDA), and they do not know the long-term effects of it
yet.
Councilmember Henjum asked if there are any other drugs used for
psychiatric treatment which have similar effects to psilocybin and if they are
similarly abused. Dr. Zane stated Ketamine has been FDA approved for
severe depression, with emerging evidence for Post Traumatic Stress
Disorder (PTSD), but does have similar abuse potential.
Tasia Poinsatte, Colorado Director, Healing Advocacy Fund Colorado’s
psilocybin therapy program, The Healing Advocacy Fund, reasons behind
the use of psychedelics, psilocybin research, and Colorado timeline. She
went over the Colorado Natural Medicine Health Act, regulated access,
state programs, required safety screen, medical consult/risk review,
guardrails, Oregon statistics, and client testimonials.
Councilmember Donelson asked if clients received three doses of
psilocybin all at one time. Ms. Poinsatte stated they are generally spread
out over a course of two months. Councilmember Donelson asked if the
cost applies to all three doses. Ms. Poinsatte confirmed it does, and
insurance does not currently cover the cost of this treatment.
Councilmember Donelson asked how long patients stay at the facility after
receiving a dose of psilocybin. Ms. Poinsatte stated it varies from three
hours to five hours depending on the amount of the dose, but clients do not